Vir Biotechnology Inc (VIR)
10.10
+0.13
(+1.30%)
USD |
NASDAQ |
Mar 27, 16:00
10.24
+0.14
(+1.39%)
Pre-Market: 08:11
Vir Biotechnology Cash from Investing (TTM): 164.63M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 164.63M |
September 30, 2023 | 116.30M |
June 30, 2023 | -487.35M |
March 31, 2023 | -989.99M |
December 31, 2022 | -1.193B |
September 30, 2022 | -1.418B |
June 30, 2022 | -681.44M |
March 31, 2022 | -333.74M |
December 31, 2021 | -140.81M |
Date | Value |
---|---|
September 30, 2021 | 297.48M |
June 30, 2021 | 38.24M |
March 31, 2021 | -26.55M |
December 31, 2020 | -9.862M |
September 30, 2020 | -144.34M |
June 30, 2020 | 88.33M |
March 31, 2020 | 122.22M |
December 31, 2019 | -256.16M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-1.418B
Minimum
Sep 2022
297.48M
Maximum
Sep 2021
-285.55M
Average
-140.81M
Median
Dec 2021
Cash from Investing (TTM) Benchmarks
Regeneron Pharmaceuticals Inc | -3.185B |
Vistagen Therapeutics Inc | -0.5606M |
Immuneering Corp | 7.296M |
SeaStar Medical Holding Corp | -- |
NovaBay Pharmaceuticals Inc | -0.017M |